Late stage pipeline
Focus on Innovation and Science to unlock mid-term potential
Pipeline updated as of January 2025
| Molecule | Indication | Phase I | Phase II | Phase III | Under Registration | Geography |
|---|---|---|---|---|---|---|
| Recent approvals | ||||||
|
Efinaconazole
|
Onychomycosis
|
|
|
|||
| Life-cycle management (label extension) | ||||||
|
Sarecycline
|
Acne
|
|
|
|||
|
Tirbanibulin
|
Actinic keratosis (LF)
|
|
|
|||
|
Tildrakizumab
|
Psoriatic arthritis
|
|
|
|||
|
Lebrikizumab
|
Atopic Dermatitis pediatric
|
|
|
|||
| NMEs | ||||||
|
Anti-IL-21 mAb
|
Autoinmune dermatology
|
|
|
|||
|
Anti-IL-1RAP mAb
|
Autoinmune dermatology
|
|
|
|||
|
IL-2muFc
|
Autoinmune disease
|
|
*
|
|||
|
ZKN-013
|
Rare Dermatology
|
|
|
|||
* Worldwide ex-Greater China